Browse by Series:

FDA Approves MM-398, T-VEC, and Trabectedin, Cabozantinib RCC FDA Submission Started, New Pembrolizumab Data, and More

Laura Jones
Published: Saturday, Oct 31, 2015

Slider Left
Slider Right
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication